Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents

This review examines the prognostic value of minimal residual disease status in patients with chronic lymphocytic leukemia undergoing treatment with novel therapeutics.

http://ift.tt/2vMOflM